Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease
By Adria Calatayud
Sanofi and Regeneron Pharmaceuticals got approval from European Union regulators for their Dupixent drug as a therapy for chronic obstructive pulmonary disease, adding a new indication for their blockbuster drug.
The companies said Wednesday the latest approval from the European Medicines Agency means the anti-inflammatory drug has now been authorized for six indications in the EU and seven globally. Further regulatory submissions are currently under review, including in the U.S., China and Japan, they said.
The EU medicines regulator is the first authority in the world to approve Dupixent for COPD patients, a disease often linked to smoking and exposure to noxious particles for which there have been no new treatment approaches in more than a decade, the companies said.
Sanofi and Regeneron are jointly developing Dupixent under a global collaboration agreement.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 03, 2024 01:38 ET (05:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations